Apyx Medical Corporation

NASDAQ:APYX

Medical - Devices

Healthcare
$2.49 -1.90%

-$0.08 today

Market cap
$104.89M
Beta
1.39
P/E (TTM)
-19.0
EPS (TTM)
-$0.22
52W Low $1.59High $5.08

Volume 0.19M

Average 0.18M

APYX Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Apyx Medical CorporationNASDAQ: APYX

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 37.4%

Gross margin was 37.4% in Q1 FY2026, down 22.7 pp from a year earlier. On a trailing-twelve-month basis it was 32.3%, down 19.3 pp year over year. Over 3 fiscal years it narrowed by 29.4 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
37.4%+47.9 pp QoQ
Last fiscal yearDec 2025
36.0%-25.0 pp YoY
LTMMar 2026
32.3%-19.3 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-22.7 pp——
1 year-25.0 pp——
3 years-29.4 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
36.0%
Year-over-year change
-25.0pp

Gross Margin vs competitors

How APYX compares with its peers on the latest reported figures

  • APYX's LTM Mar 2026 gross margin of 32.3% is the 3rd highest of the 7 companies compared; the peer median is 20.1%.
  • Its year-over-year change of -19.3 pp is the 6th highest of 7, against a peer median of +0.3 pp.
  • Over three fiscal years its change of -29.4 pp compares with a peer median of +3.6 pp.
APYX Competitors Peer median
Gross Margin for APYX and competitors
Company Period LTM level YoY 3-year change
RCELAVITA Medical, Inc.LTM Mar 202681.4% -4.1 pp-0.3 pp
XTNTXtant Medical Holdings, Inc.LTM Mar 202662.3% +4.2 pp+7.5 pp
APYXApyx Medical CorporationLTM Mar 202632.3% -19.3 pp-29.4 pp
PDEXPro-Dex, Inc.LTM Mar 202627.8% -3.6 pp-1.9 pp
RPIDRapid Micro Biosystems, Inc.LTM Mar 202612.4% +6.3 pp+72.5 pp
LUCDLucid Diagnostics Inc.LTM Mar 2026-40.0% +27.6 pp+798.4 pp
SERASera Prognostics, Inc.LTM Mar 2026-191.2% -199.9 pp-130.5 pp
VANIVivani Medical, Inc.FY2025— ——
Peer median (excluding APYX) 20.1%+0.3 pp+3.6 pp

Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.52M44.51M52.35M48.1M52.84M
Cost of Revenue14.92M15.38M18.59M18.74M33.81M
Gross Profit33.6M29.13M33.76M29.36M19.03M
Gross Margin69.3%65.4%64.5%61.0%36.0%
Research & Development4.32M4.54M4.84M5.08M3.37M
Selling, General & Admin43.73M48.15M48.87M43.13M36.12M
Operating Expenses48.05M52.69M51.02M48.21M25.48M
Depreciation & Amortization903K890K692K599K655K
EBITDA(13.91M)(22.01M)(18.11M)(16.8M)(4.59M)
EBITDA Margin-28.7%-49.4%-34.6%-34.9%-8.7%
Operating Income(14.45M)(23.56M)(17.26M)(18.85M)(6.45M)
Operating Margin-29.8%-52.9%-33.0%-39.2%-12.2%
Interest Income11K157K921K1.61M1.11M
Interest Expense10K15K2.48M5.91M5.59M
Other Income / Expenses(372K)651K(4.02M)(4.46M)(4.39M)
Income Before Tax(14.82M)(22.91M)(21.28M)(23.31M)(10.84M)
Pre-Tax Margin-30.5%-51.5%-40.7%-48.5%-20.5%
Income Tax Expense380K367K(2.43M)252K270K
Net Income(15.17M)(23.18M)(18.71M)(23.46M)(11.21M)
Net Margin-31.3%-52.1%-35.7%-48.8%-21.2%
EPS (Basic)(0.44)(0.67)(0.54)(0.66)(0.27)
EPS (Diluted)(0.44)(0.67)(0.54)(0.66)(0.27)
Weighted Avg Shares34.33M34.52M34.62M35.54M42.16M
Weighted Avg Shares (Diluted)34.33M34.52M34.62M35.54M42.16M

Apyx Medical Corporation

NASDAQ:APYX

Intrinsic Alpha fair value

Locked

Current Price

$2.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.